NCT05774535 2025-10-02
TIROVASC
Istituto Auxologico Italiano
Withdrawn
Clinical Trials
3 trialsNCT04258683 2023-08-29
A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE
Canadian Myeloma Research Group
Phase 2 Withdrawn
NCT04361669 2022-09-07
Hospice Quality Score Assessment Post Pharmacist Intervention
Tabula Rasa HealthCare
Withdrawn